Ligand-mediated controlled drug delivery
First Claim
1. A method for defining a controlled rate of release of a first biologically active agent from a polymeric carrier matrix comprising:
- forming a polymeric carrier matrix;
loading an amount of a first polypeptide ligand into the polymeric carrier matrix, the first polypeptide ligand having an affinity for the first biologically active agent, the first biologically active agent being a protein; and
binding at least a portion of the first biologically active agent to at least a portion of the first polypeptide ligand with a reversible, non-covalent bond between the first polypeptide ligand and the first biologically active agent to form a first polypeptide ligand/first biologically active agent complex, wherein the complex is formed prior to loading the first polypeptide ligand into the polymeric matrix, the affinity of the first polypeptide ligand for the first biologically active agent being described by an equilibrium dissociation constant, KD that is defined according to the equilibrium relationship;
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are systems and methods that can be utilized to define and control the delivery rate of a biological agent from a carrier matrix such as a biocompatible hydrogel. The carrier matrices of the present invention can include ligands incorporated within the matrix at a predetermined concentration level (CLT). In addition, the ligands within the matrix can display a particular, predetermined affinity for the biologically active agents to be delivered by the system. In particular, the affinity between the ligand and the biologically active agent can have a known predetermined dissociation constant (KD). When utilizing the system, the agent can be incorporated within the matrix due to association of the agent with the ligand. In addition, the agent can be protected from side reactions due to the association of the agent with the ligand. Through particular selection of the parameters CLT and KD, the rate of release of the biologically active agent from the matrix can be controlled. The disclosed methods and systems can be advantageously used in both in vivo clinical settings and ex vivo settings, such as tissue engineering applications.
-
Citations
42 Claims
-
1. A method for defining a controlled rate of release of a first biologically active agent from a polymeric carrier matrix comprising:
-
forming a polymeric carrier matrix; loading an amount of a first polypeptide ligand into the polymeric carrier matrix, the first polypeptide ligand having an affinity for the first biologically active agent, the first biologically active agent being a protein; and binding at least a portion of the first biologically active agent to at least a portion of the first polypeptide ligand with a reversible, non-covalent bond between the first polypeptide ligand and the first biologically active agent to form a first polypeptide ligand/first biologically active agent complex, wherein the complex is formed prior to loading the first polypeptide ligand into the polymeric matrix, the affinity of the first polypeptide ligand for the first biologically active agent being described by an equilibrium dissociation constant, KD that is defined according to the equilibrium relationship; - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method for defining a controlled rate of release of a biologically active agent from a polymeric carrier matrix comprising:
-
combining multifunctional monomers or macromers with a polymerization initiator; inducing the polymerization initiator to polymerize the multifunctional monomers or macromers to form a polymeric carrier matrix; loading an amount of a polypeptide ligand into the polymeric carrier matrix, the polypeptide ligand having an affinity for the biologically active agent; and binding at least a portion of the biologically active agent to at least a portion of the polypeptide ligand with a reversible, non-covalent bond between the polypeptide ligand and the biologically active agent to form a polypeptide ligand/biologically active agent complex, the biologically active agent being a protein, the affinity of the polypeptide ligand for the biologically active agent being described by an equilibrium dissociation constant, KD that is defined according to the equilibrium relationship; - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
-
29. A method for defining a biphasic controlled rate of release of a biologically active agent from a polymeric carrier matrix comprising:
-
forming a polymeric carrier matrix; loading an amount of a polypeptide ligand into the polymeric carrier matrix, the polypeptide ligand having an affinity for the biologically active agent, the biologically active agent being a protein; loading an amount of the biologically active agent into the polymeric carrier matrix, wherein the ratio of the amount of the polypeptide ligand loaded into the polymeric carrier matrix to the amount of the biologically active agent loaded into the polymeric carrier matrix is less than unity; binding at least a portion of the biologically active agent to at least a portion of the polypeptide ligand with a reversible, non-covalent bond between the polypeptide ligand and the biologically active agent to form a polypeptide ligand/biologically active agent complex, the affinity of the polypeptide ligand for the biologically active agent being described by an equilibrium dissociation constant, KD that is defined according to the equilibrium relationship; - View Dependent Claims (30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
Specification